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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Symbiosal
®
 and lowering of blood pressure and reduced risk of 
hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Han-Asiabiotech GmbH, submitted for authorisation of a health claim pursuant to 
Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to Symbiosal
®
 and lowering of blood pressure and reduced risk of hypertension. The 
Panel considers that the food, Symbiosal
®
, which is the subject of the health claim, and the food, table salt, which 
Symbiosal
®
 should replace, are sufficiently characterised. Lowering of blood pressure is a beneficial 
physiological effect for people who want to lower their blood pressure. Increased blood pressure is a risk factor 
for hypertension. In weighing the evidence, the Panel took into account that one human study with 
methodological limitations showed a decrease in blood pressure when Symbiosal
®
 was consumed instead of table 
salt for eight weeks in the context of a salt-restricted diet, but that no other human studies in which these results 
have been replicated were provided, that the animal studies did not support the results of the human study and 
that no evidence was provided for a mechanism by which the food could exert the claimed effect. The Panel 
concludes that a cause and effect relationship has not been established between the consumption of Symbiosal
®
 
instead of table salt and lowering of blood pressure. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Han-Asiabiotech GmbH, submitted for authorisation of a health claim 
pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion 
on the scientific substantiation of a health claim related to Symbiosal
®
 and lowering of blood pressure 
and reduced risk of hypertension. 
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is Symbiosal
®
, which, according to the applicant, 
should replace table salt (i.e. sodium chloride, NaCl) in order to obtain the claimed effect. NaCl is a 
well characterised salt. Symbiosal
®
 is produced by mixing sea salt (97 %) with chitosan (3 %), 
following a patented manufacturing process. Chitosan is a linear cationic polysaccharide composed of 
randomly distributed -(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine. The Panel considers 
that the food, Symbiosal
®
, which is the subject of the health claim, and the food, table salt (i.e. NaCl), 
which Symbiosal
®
 should replace, are sufficiently characterised. 
The claimed effect proposed by the applicant is “lowers the rising of blood pressure when used as a 
replacement of traditional table salt. The rising of blood pressure is a risk factor for hypertension”. 
The target population proposed by the applicant is “healthy mild hypertensive subjects, and people 
who want/need to lower the rising of their blood pressure”. The Panel considers that lowering of 
blood pressure is a beneficial physiological effect for people who want to lower their blood pressure. 
Increased blood pressure is a risk factor for hypertension. 
The applicant provided one human intervention study which assessed the effect of Symbiosal
®
 on 
blood pressure when replacing table salt in the context of a salt-restricted diet. In this randomised, 
double-blind, cross-over study, 40 individuals with stage 1 hypertension received 3 g/day Symbiosal
®
 
or 3 g/day table salt (both as added salt in the diet). The two cross-over periods lasted eight weeks 
each and were separated by a washout of two weeks. Results of a paired t-test on the intention-to-treat 
population indicated that the reductions of systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) were higher when Symbiosal
®
 was consumed instead of table salt (SBP: 8.7 ± 10.8 mmHg vs. 
−3.2 ± 8.5 mmHg, p = 0.0156; DBP: −7.2 ± 8.0 mmHg vs. −3.7 ± 7.4 mmHg, p = 0.0285). Similar 
results were obtained in a “per protocol” analysis. Highly significant period effects were observed for 
SBP and DBP, i.e. most of the reductions in blood pressure were observed during the first cross-over 
period. The Panel notes that significant period effects were observed for SBP and DBP. The Panel 
also notes that blood pressure did not return to baseline after the washout period. The Panel notes the 
limitations of the paired t-test for the analysis of cross-over designs when there are carry over and/or 
period effects. The Panel considers that this study with methodological limitations showed a decrease 
in SBP and DBP when 3 g Symbiosal
®
 per day was consumed instead of table salt as added salt for 
eight weeks accompanied by a salt-restricted diet. 
The Panel considers that the animal studies did not support the human study and that no evidence was 
provided for a mechanism by which Symbiosal
®
 could lower blood pressure when consumed instead 
of table salt. 
In weighing the evidence, the Panel took into account that one human study with methodological 
limitations showed a decrease in blood pressure when Symbiosal
®
 was consumed instead of table salt 
for eight weeks in the context of a salt-restricted diet, but that no other human studies in which these 
results have been replicated were provided, that the animal studies did not support the results of the 
human study and that no evidence was provided for a mechanism by which the food could exert the 
claimed effect. 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Symbiosal
®
 instead of table salt and lowering of blood pressure. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 20/05/2014. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. The application included a request for the protection of proprietary data. 
 On 28/07/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 28/08/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 03/09/2014. 
 On 16/10/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the 
scientific evaluation was suspended on 30/10/2014, in compliance with Article 16(1) of 
Regulation (EC) No 1924/2006. 
 On 22/12/2014, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
 On 06/02/2015, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application and the scientific evaluation was 
suspended on 19/02/2015, in compliance with Article 16(1) of Regulation (EC) No 
1924/2006. 
 On 15/04/2015, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
 During its meeting on 11/06/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Symbiosal
®
 and 
lowering of blood pressure. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
Symbiosal
®
 and lowering of blood pressure 
 
 
EFSA Journal 2015;13(7):4147 6 
opinion on the scientific substantiation of a health claim related to: Symbiosal
®
 and lowering of blood 
pressure and reduced risk of hypertension. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of Symbiosal
®
, a positive assessment of its safety, nor a decision on whether Symbiosal
®
 is, 
or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
Symbiosal
®
 and lowering of blood pressure 
 
 
EFSA Journal 2015;13(7):4147 7 
INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
Han-Asiabiotech GmbH, Industriestrasse 1, D-77731 Willstätt, Germany. 
The application includes a request for the protection of proprietary data, in accordance with Article 21 
of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is Symbiosal
®
, which is a 
food supplement containing sea salt (97 %) plus chitosan (3 %). 
Health relationship as claimed by the applicant 
According to the applicant, consumption of Symbiosal
®
 instead of standard table salt lowers blood 
pressure, thereby lowering the risk of hypertension. The applicant indicated “rising of blood pressure” 
as the risk factor and “high blood pressure (hypertension)” as the disease. 
With regards to the mechanism by which the food would exert the claimed effect, the applicant 
indicated that the mechanism is not clearly known but that some findings suggest that chitosan may 
inhibit the increase of angiotensin-converting enzyme induced by an acute salt intake. The applicant 
also claimed that this inhibition might be mediated by blocking or counteracting the hypertensive 
effect of the chloride ions in sodium chloride (NaCl). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Symbiosal has been shown 
to lower the rising of blood pressure when used as a replacement of traditional table salt. The rising of 
blood pressure is a risk factor for high blood pressure (hypertension)”. 
Specific conditions of use as proposed by the applicant 
The applicant proposes to replace standard table salt in the diet by Symbiosal
®
, up to a maximum total 
added salt intake of 3 g per day. This salt replacement (and restriction to the maximum of 3 g per day) 
should be accompanied by other lifestyle improvements, such as eating less fat and sugar and 
increasing physical exercise. 
The target population proposed by the applicant are “mild hypertensive” subjects, and “people who 
want/need to lower the rising of their blood pressure”. 
Children, pregnant women and lactating women should not consume Symbiosal
®
. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is Symbiosal
®
, which, according to the applicant, 
should replace table salt (i.e. NaCl) in order to obtain the claimed effect (i.e. lowering of blood 
pressure). 
NaCl is a well characterised salt constituted by sodium and chloride in a 1:1 molar ratio. 
Symbiosal
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It is well established that high sodium intakes, mainly as NaCl (table salt), increase blood pressure, 
and that reducing dietary NaCl intakes helps to maintain a normal blood pressure (EFSA NDA Panel, 
2011). 
Symbiosal
®
 is produced by mixing sea salt (97 %) with chitosan (3 %), following a patented 
manufacturing process (United States patent no 7.335.766 B2, Korean patent no 0520007). Chitosan 
is a linear cationic polysaccharide composed of randomly distributed -(1-4)-linked D-glucosamine 
and N-acetyl-D-glucosamine produced by partial deacetylation of chitin, which is a component of the 
exoskeleton of crustaceans and the cell walls of fungi. 
An overview of the manufacturing process of Symbiosal
®
 and information regarding its stability were 
provided. 
Following a request for clarification of the active constituent in Symbiosal
®
, the applicant indicated 
that “Symbiosal® is not only a combination of NaCl with chitosan but a specific product where the 
combination of these substances follows a patented process”. The applicant also claimed “that the 
hypertensive power of the salt contained in Symbiosal
®
 has been reduced by the effect of the 
combination with chitosan according to a specific patented process”. 
The Panel considers that the food, Symbiosal
®
, which is the subject of the health claim, and the food, 
table salt (i.e. NaCl), which Symbiosal
®
 should replace, are sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “lowers the rising of blood pressure when used as a 
replacement of traditional table salt. The rising of blood pressure is a risk factor for hypertension”. 
The target population proposed by the applicant is “healthy mild hypertensive subjects, and people 
who want/need to lower the rising of their blood pressure”. 
Blood pressure is the pressure (force per unit area) exerted by circulating blood on the walls of blood 
vessels. Hypertension, defined by convention as blood pressure above 140 mmHg (systolic) and/or 
90 mmHg (diastolic), may compromise normal arterial and cardiac function. 
The Panel considers that lowering of blood pressure is a beneficial physiological effect for people 
who want to lower their blood pressure. Increased blood pressure is a risk factor for hypertension. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, Cochrane Library, Science Direct, Scirus, 
Springerlink and Wiley Interscience using the search terms “Symbiosal®”, “salt”, “NaCl”, “chitosan”, 
“blood pressure”, “hypertension”, “systolic” and “supplementation”. Publications in English, French 
and Spanish were accepted. In addition, reference lists of retrieved articles were searched manually to 
identify relevant studies. Trials were included if they were “well designed” (i.e. randomised and 
blinded, with an adequate number of subjects). Studies in subjects on blood pressure lowering 
medication were excluded. 
Symbiosal
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3.1. Studies investigating the effect of the food on blood pressure  
3.1.1. Human studies 
The applicant provided one human intervention study (Allaert, 2013a, b, unpublished, study report, 
claimed as proprietary by the applicant), which assessed the effect of the food (i.e. Symbiosal
®
) on 
blood pressure when replacing table salt in the context of a salt-restricted diet. 
In this randomised, double-blind, controlled, multi-centre, cross-over study, 40 individuals (mean age 
58.6 ± 12 years; mean body mass index 26.4 ± 4.9 kg/m
2
; 24 women) with “mild hypertension” (mean 
± standard deviation systolic blood pressure (SBP) 149.4 ± 4.7 mmHg) received 3 g/day Symbiosal
®
 
or 3 g/day table salt (both as added salt in the diet). The two cross-over periods lasted eight weeks 
each and were separated by a washout of two weeks. In order to be included in the study, participants 
had to have stage 1 hypertension (SBP 140-159 mmHg, or diastolic blood pressure (DBP) 
90-99 mmHg) without receiving any antihypertensive treatment. 
Power calculations indicated that considering a standard deviation of 15 mmHg, 15 study subjects per 
group would yield a power of 90 % (for α = 0.05) to detect a difference in SBP of 10 mmHg between 
Symbiosal
®
 and table salt (Allaert, 2013b, unpublished). In order to anticipate losses, 20 participants 
per group were recruited. Recruitment took place at 13 medical centres (practitioners), with one to 
four patients recruited per centre. 
The study participants were instructed not to eat liquorice, to follow lifestyle advice about physical 
exercise and nutrition (e.g. to eat less fat and less sugar) and to restrict their added salt intake to a 
maximum of 3 g/day. There was no run-in period prior to the intervention. Participants were asked to 
use the dispensed saltcellars, which contained either Symbiosal
®
 or table salt. In order to test 
consumption, the saltcellars were weighed at the end of each cross-over period. Salt consumption was 
comparable between the groups (first cross-over period, NaCl: 3.0 ± 1.5 g/day, Symbiosal
®
: 2.9 ± 
1.6 g/day; second cross-over period, NaCl: 3.3 ± 2.4 g/day, Symbiosal
®
: 3.0 ± 1.7 g/day). The 
background diet (apart from alcohol consumption) of the study participants was not assessed. Twenty-
four-hour urinary sodium analyses/ionograms were provided. There were no significant differences 
between the periods. Two subjects dropped out of the study (one subject withdrew for personal 
reasons and one subject dropped out because of an adverse event). 
Blood pressure was measured at week 0 (i.e. baseline), week 8 (i.e. end of the first cross-over period), 
week 10 and week 18 (i.e. end of the second cross-over period) by a medical practitioner. Following a 
request for specifications of the protocol applied, the applicant indicated that blood pressure was 
measured (using a homologate electronic measuring device) with study participants in a sitting 
position, after a 10-minute rest, and at three different time points separated by 3-minute intervals. The 
average of the three measurements was used. 
Treatment effects were investigated using two-way analysis of variance (ANOVA). Carry-over 
analysis was performed to determine whether any carry-over correction was necessary. Where no 
significant carry-over effect was found, the model was simplified by removing this effect. When the 
ANOVA indicated an overall treatment effect (i.e. p < 0.05), comparisons between the means of the 
two interventions (i.e. Symbiosal
®
 or NaCl) were performed using a two-sided paired t-test. The 
statistical analysis was applied on the intention-to-treat population (ITT, n = 40, i.e. all randomised 
participants, with the last observation carried forward for missing data) and on the “per protocol” 
population (n = 37, i.e. all randomised participants minus two dropouts, minus one participant who 
lacked the washout period). Results of the paired t-test on the ITT population indicated that the 
reductions of SBP and DBP were higher when Symbiosal
®
 was consumed instead of table salt (SBP: 
−8.7 ± 10.8 mmHg vs. −3.2 ± 8.5 mmHg, p = 0.0156; DBP: −7.2 ± 8.0 mmHg vs. −3.7 ± 7.4 mmHg, 
p = 0.0285). Similar results were obtained for the “per protocol” analysis. Highly significant period 
effects were observed for SBP (p = 0.0006) and DBP (p < 0.0001), i.e. most of the reductions in blood 
Symbiosal
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pressure were observed during the first cross-over period. Variability between centres was not taken 
into account in the analysis. 
The Panel notes that significant period effects were observed for SBP and DBP. The Panel also notes 
that blood pressure did not return to baseline after the washout period (SBP: 137.1 ± 9.4 mmHg 
(week 10) vs. 149.2 ± 4.9 mmHg (week 0, baseline) in the Symbiosal
®
-first group; 
144.0 ± 10.7 mmHg (week 10) vs. 149.7 ± 4.6 mmHg (week 0, baseline) in the NaCl-first group). The 
Panel notes the limitations of the paired t-test for the analysis of cross-over designs when there are 
carry-over and/or period effects. 
The Panel considers that this study with methodological limitations showed a decrease in SBP and 
DBP when 3 g Symbiosal
®
 per day was consumed instead of table salt as added salt for eight weeks 
accompanied by a salt-restricted diet. 
3.1.2. Animal studies 
The applicant provided four publications (Kim et al., 2004; Kim et al., 2005; Park et al., 2009; Kim et 
al., 2010) which reported on five animal studies. 
One animal study (Kim et al., 2004) was provided in Korean only, which did not allow a scientific 
evaluation by the Panel. Therefore, no conclusions can be drawn from this study. 
The remaining four animal studies (Kim et al., 2005; Park et al., 2009; Kim et al., 2010 (reporting on 
two animal studies)) were reported to have been performed with various chitosan-containing salts. 
Upon request for clarification, the applicant claimed that, even though it is not mentioned in the 
publications, the chitosan salt used in the studies by Kim et al. (2005), Park et al. (2009) and Kim et 
al. (2010) was Symbiosal
®
, produced according to the patented manufacturing process, and that the 
owner of the patent, Biotech in Mokpo, Korea, co-authored the papers. 
In one animal study (Kim et al., 2005), spontaneously hypertensive rats (SHRs) were fed for eight 
weeks a diet containing chitosan salt (3 %) (claimed by the applicant to have been Symbiosal
®
), a diet 
containing commercial salt (3 %) or a control diet (seven rats per group). At the end of the study 
period, no significant differences in blood pressure between the groups were reported. 
In the animal study by Park et al. (2009), SHRs were administered for two months (i) NaCl plus 3 % 
chitosan (claimed by the applicant to have been Symbiosal
®
), (ii) NaCl plus potassium chloride (KCl), 
(iii) NaCl, (iv) chitosan or (v) untreated control diet (five animals per group). The concentration of 
sodium given was 44 mM (1 g of sodium) per day. There were no statistically significant differences 
in blood pressure between the animals receiving the three salts at the end of the study. 
One publication (Kim et al., 2010) reported on two animal studies and one in vitro study. One animal 
study was carried out in normotensive Sprague-Dawley rats and did not find any effects of chitosan 
salt (3 %) on blood pressure compared with table salt. The second study was performed in SHRs fed 
for five weeks (i) control diet (0 % salt), (ii) control diet plus captopril, (iii) a diet with 3 % chitosan 
salt (claimed to be Symbiosal
®
) or (iv) a diet with 3 % commercial salt (six rats per group). After five 
weeks, the rats in the chitosan salt group had a significantly lower SBP (p < 0.001, two-way ANOVA) 
than rats on the diet with commercial salt. 
The Panel notes that four animal studies, i.e. three studies in SHRs and one study in normotensive 
rats, have been provided. Only one study (Kim et al., 2010), which used SHRs, showed a decrease in 
blood pressure when Symbiosal
®
 was consumed instead of table salt. 
The Panel considers that the animal studies do not support the results of the human study. 
Symbiosal
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3.2. Studies on the mechanism by which the food could exert the claimed effect 
The applicant indicated that the mechanism by which the food might exert the claimed effect is not 
clearly known but that some findings suggest that chitosan may inhibit the increase of angiotensin-
converting enzyme (ACE) induced by an acute salt intake. The applicant also claimed that this 
“inhibition might be mediated by blocking or counteracting the hypertensive effect of the chloride 
ions in NaCl”. 
The applicant provided three animal studies (Kim et al., 2004, 2005; Park et al., 2009) in support of a 
mechanism by which Symbiosal
® 
or other chitosan-containing salts could exert the claimed effect. 
One animal study (Kim et al., 2004) was provided in Korean only, which did not allow a scientific 
evaluation by the Panel. Therefore, no conclusions can be drawn from this study. 
In one animal study (Kim et al., 2005), SHRs were fed with “chitosan-salt (3 %)” (claimed by the 
applicant to have been Symbiosal
®
) diet, “commercial-salt (3 %)” diet or a control diet for eight 
weeks. ACE inhibition activity was measured in plasma according to the method by Chushman and 
Cheung (1971). The results of this assay were reported as descriptive statistics only. The Panel 
considers that no conclusions can be drawn from this study. 
In the animal study by Park et al. (2009), SHRs were fed for two months (i) NaCl plus 3 % chitosan 
(claimed by the applicant to have been Symbiosal
®
), (ii) NaCl plus KCl, (iii) NaCl, (iv) chitosan or 
(v) an untreated control diet. At the end of the study, ACE-I and ACE-II concentrations were 
measured in serum (using rat angiotensin I and II enzyme immunoassay kits). There were no 
statistically significant differences in ACE I or ACE II serum concentrations between the groups. 
The Panel considers that no evidence was provided for a mechanism by which Symbiosal
®
 could 
lower blood pressure when consumed instead of table salt. 
3.3. Weighing the evidence 
In weighing the evidence, the Panel took into account that one human study with methodological 
limitations showed a decrease in blood pressure when Symbiosal
®
 was consumed instead of table salt 
for eight weeks in the context of a salt-restricted diet, but that no other human studies in which these 
results have been replicated were provided, that the animal studies did not support the results of the 
human study and that no evidence was provided for a mechanism by which the food could exert the 
claimed effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Symbiosal
®
 instead of table salt and lowering of blood pressure. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, Symbiosal®, which is the subject of the health claim, and the food, table salt (i.e. 
NaCl), which Symbiosal
®
 should replace, are sufficiently characterised. 
 The claimed effect proposed by the applicant is “lowers the rising of blood pressure when 
used as a replacement of traditional table salt. The rising of blood pressure is a risk factor for 
hypertension”. The target population proposed by the applicant is “healthy mild hypertensive 
subjects, and people who want/need to lower the rising of their blood pressure”. Lowering of 
blood pressure is a beneficial physiological effect for people who want to lower their blood 
pressure. Lowering of blood pressure reduces the risk of hypertension. 
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 A cause and effect relationship has not been established between the consumption of 
Symbiosal
®
 instead of table salt and lowering of blood pressure. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Symbiosal
®
 and lowering of blood pressure and reduced risk of 
hypertension pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0415_DE). 
Month 2014. Submitted by Han-Asiabiotech GmbH. 
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ABBREVIATIONS 
ACE  angiotensin-converting enzyme 
ANOVA analysis of variance 
DBP  diastolic blood pressure 
ITT  intention-to-treat population 
SBP  systolic blood pressure 
SHR  spontaneously hypertensive rat 
